Julien Mazieres, Head of Thoracic Diseases Department at the University Hospital Center of Toulouse, shared a post on X:
“Divarasib significantly improved PFS (9.8 vs 5.7 m) and OS (12 vs 17.7) vs control (soto or ada) with a manageable safety profile (GI toxicity) in previously treated advanced/metastatic KRAS G12C-mutated NSCLC.”
You can also read:
